Anti-spike, Anti-nucleocapsid and Neutralizing ...
Document type :
Compte-rendu et recension critique d'ouvrage
PMID :
Title :
Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals
Author(s) :
Brochot, Etienne [Auteur]
Laboratoire de Virologie [CHU Amiens]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
Demey, Baptiste [Auteur]
Laboratoire de Virologie [CHU Amiens]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
Touzé, Antoine [Auteur]
Infectiologie et Santé Publique [UMR ISP]
Belouzard, Sandrine [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Dubuisson, Jean [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Schmit, Jean-Luc [Auteur]
Laboratoire de Virologie [CHU Amiens]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
Duverlie, Gilles [Auteur]
Laboratoire de Virologie [CHU Amiens]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
François, Catherine [Auteur]
Laboratoire de Virologie [CHU Amiens]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
Castelain, Sandrine [Auteur]
Laboratoire de Virologie [CHU Amiens]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
Helle, Francois [Auteur correspondant]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
Laboratoire de Virologie [CHU Amiens]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
Demey, Baptiste [Auteur]
Laboratoire de Virologie [CHU Amiens]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
Touzé, Antoine [Auteur]
Infectiologie et Santé Publique [UMR ISP]
Belouzard, Sandrine [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Dubuisson, Jean [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Schmit, Jean-Luc [Auteur]
Laboratoire de Virologie [CHU Amiens]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
Duverlie, Gilles [Auteur]
Laboratoire de Virologie [CHU Amiens]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
François, Catherine [Auteur]
Laboratoire de Virologie [CHU Amiens]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
Castelain, Sandrine [Auteur]
Laboratoire de Virologie [CHU Amiens]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
Helle, Francois [Auteur correspondant]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
Journal title :
Frontiers in Microbiology
Pages :
8 p.
Publisher :
Frontiers Media
Publication date :
2020
ISSN :
1664-302X
English keyword(s) :
SARS-CoV-2
COVID-19
spike
nucleocapsid
neutralizing antibodies
vaccine
convalescent plasma therapy
COVID-19
spike
nucleocapsid
neutralizing antibodies
vaccine
convalescent plasma therapy
HAL domain(s) :
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Maladies infectieuses
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Maladies émergentes
Sciences du Vivant [q-bio]/Immunologie/Immunité adaptative
Sciences du Vivant [q-bio]/Microbiologie et Parasitologie/Virologie
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Maladies émergentes
Sciences du Vivant [q-bio]/Immunologie/Immunité adaptative
Sciences du Vivant [q-bio]/Microbiologie et Parasitologie/Virologie
English abstract : [en]
A better understanding of the anti-SARS-CoV-2 immune response is necessary to finely evaluate commercial serological assays but also to predict protection against reinfection and to help the development of vaccines. For ...
Show more >A better understanding of the anti-SARS-CoV-2 immune response is necessary to finely evaluate commercial serological assays but also to predict protection against reinfection and to help the development of vaccines. For this reason, we monitored the anti-SARS-CoV-2 antibody response in infected patients. In order to assess the time of seroconversion, we used 151 samples from 30 COVID-19 inpatients and monitored the detection kinetics of anti-S1, anti-S2, anti-RBD and anti-N antibodies with in-house ELISAs. We observed that specific antibodies were detectable in all inpatients 2 weeks post-symptom onset and that the detection of the SARS-CoV-2 Nucleocapsid and RBD was more sensitive than the detection of the S1 or S2 subunits. Using retroviral particles pseudotyped with the spike of the SARS-CoV-2, we also monitored the presence of neutralizing antibodies in these samples as well as 25 samples from asymptomatic individuals that were shown SARS-CoV-2 seropositive using commercial serological tests. Neutralizing antibodies reached a plateau 2 weeks post-symptom onset and then declined in the majority of inpatients but they were undetectable in 56% of asymptomatic patients. Our results indicate that the SARS-CoV-2 does not induce a prolonged neutralizing antibody response. They also suggest that induction of neutralizing antibodies is not the only strategy to adopt for the development of a vaccine. Finally, they imply that anti-SARS-CoV-2 neutralizing antibodies should be titrated to optimize convalescent plasma therapy.Show less >
Show more >A better understanding of the anti-SARS-CoV-2 immune response is necessary to finely evaluate commercial serological assays but also to predict protection against reinfection and to help the development of vaccines. For this reason, we monitored the anti-SARS-CoV-2 antibody response in infected patients. In order to assess the time of seroconversion, we used 151 samples from 30 COVID-19 inpatients and monitored the detection kinetics of anti-S1, anti-S2, anti-RBD and anti-N antibodies with in-house ELISAs. We observed that specific antibodies were detectable in all inpatients 2 weeks post-symptom onset and that the detection of the SARS-CoV-2 Nucleocapsid and RBD was more sensitive than the detection of the S1 or S2 subunits. Using retroviral particles pseudotyped with the spike of the SARS-CoV-2, we also monitored the presence of neutralizing antibodies in these samples as well as 25 samples from asymptomatic individuals that were shown SARS-CoV-2 seropositive using commercial serological tests. Neutralizing antibodies reached a plateau 2 weeks post-symptom onset and then declined in the majority of inpatients but they were undetectable in 56% of asymptomatic patients. Our results indicate that the SARS-CoV-2 does not induce a prolonged neutralizing antibody response. They also suggest that induction of neutralizing antibodies is not the only strategy to adopt for the development of a vaccine. Finally, they imply that anti-SARS-CoV-2 neutralizing antibodies should be titrated to optimize convalescent plasma therapy.Show less >
Language :
Anglais
Popular science :
Non
Source :
Files
- https://www.frontiersin.org/articles/10.3389/fmicb.2020.584251/pdf
- Open access
- Access the document
- https://hal.archives-ouvertes.fr/hal-03058488/document
- Open access
- Access the document
- https://hal.archives-ouvertes.fr/hal-03058488/document
- Open access
- Access the document
- document
- Open access
- Access the document
- fmicb-11-584251.pdf
- Open access
- Access the document
- Open access
- Access the document